Holen Sie sich die Stockscreener-App
55.92
2.55%
1.364
Schlusskurs vom Vortag:
$54.56
Offen:
$54.72
24-Stunden-Volumen:
302.26K
Relative Volume:
0.42
Marktkapitalisierung:
$3.21B
Einnahmen:
$665.13M
Nettoeinkommen (Verlust:
$64.50M
KGV:
48.88
EPS:
1.1442
Netto-Cashflow:
$185.87M
1W Leistung:
-0.66%
1M Leistung:
+14.00%
6M Leistung:
+23.16%
1J Leistung:
+76.78%
1-Tages-Spanne:
$54.16
$56.49
1-Wochen-Bereich:
$52.95
$56.59
52-Wochen-Spanne:
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
55.95 | 3.13B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.52 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
489.64 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan
Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units - Stock Titan
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge? - simplywall.st
Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook - DirectorsTalk Interviews
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally? - Yahoo Finance
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus at TD Cowen Conference: Strategic Diversification Unveiled By Investing.com - Investing.com South Africa
Supernus at TD Cowen Conference: Strategic Diversification Unveiled - Investing.com
Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses - Quiver Quantitative
Supernus Pharmaceuticals 2025 10-K: $718.95M Revenue, $(0.68) EPS - TradingView
Sage acquisition and ZURZUVAE strategy reshape Supernus (NASDAQ: SUPN) - Stock Titan
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook - simplywall.st
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc. - MarketBeat
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Supernus (SUPN) SVP reports RSU vesting and tax-withholding share disposition - Stock Titan
Supernus (NASDAQ: SUPN) CFO reports RSU vesting and tax share withholding - Stock Titan
SUPERNUS (NASDAQ: SUPN) executive logs RSU grant and tax share withholding - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals stock hits 52-week high at $57.76 By Investing.com - Investing.com Australia
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch - Investing.com Nigeria
Supernus Pharmaceuticals stock hits 52-week high at $57.76 - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighTime to Buy? - MarketBeat
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains - Investing.com Nigeria
Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains By Investing.com - Investing.com UK
Supernus FY25 Total Revenues Up 9%; Guides 17-21% Growth For FY26 - RTTNews
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q4 2025 Earnings Conference - 富途牛牛
Supernus Pharmaceuticals Swings to Q4 Loss, Revenue Rises - marketscreener.com
Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns - Sahm
Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook Highlights 21% Potential Upside - DirectorsTalk Interviews
Supernus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highli - GuruFocus
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Millennium Management LLC Increases Stake in Supernus Pharmaceuticals Inc. - GuruFocus
Supernus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SUPN Sets 2026 Revenue and Earnings Guidance - GuruFocus
Supernus (SUPN) Reports Strong Q4 Revenue and Outlines Future Pl - GuruFocus
Supernus: Fourth Quarter Financial Overview - Bitget
Supernus: Q4 Earnings Snapshot - marketscreener.com
Supernus boosts executive pay with new equity incentives - TipRanks
Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Misses Expectations By $0.48 EPS - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales - Yahoo Finance
Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q4 Revenue $211.6M, vs. FactSet Est of $195.2M - marketscreener.com
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Supernus Pharmaceuticals: Q4 Earnings Insights - Benzinga
Supernus faces earnings test after Q3 shock to profitability - Investing.com India
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sensenig Bethany | Director |
Feb 19 '26 |
Option Exercise |
0.00 |
4,475 |
0 |
4,475 |
| Sensenig Bethany | Director |
Feb 19 '26 |
Sale |
51.01 |
4,475 |
228,265 |
0 |
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):